GEN News Highlights

Avid Expands for Avid Fans

(Page
1
of
1)

Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals and a contract manufacturing organization (CMO) focused on the process development and manufacturing of monoclonal antibodies, proteins, and enzymes, has completed facility upgrades in response to increasing demand for its contract manufacturing services. According to Peregrine, the demand for Avid's services has reached an all-time high, while projected revenue for its current fiscal year ending April 2013 is expected to surpass $18 million—a 20% increase from the previous fiscal year.

"We have seen tremendous growth in the demand for services at Avid, based on both the success of our clients and the continued commitment to excellence by our dedicated team," said Steven W. King, president of Avid Bioservices. "We are strategically reinvesting some of these financial resources back into the business to further increase manufacturing throughput, reduce manufacturing risks, and ensure continued reliability with redundant systems."

According to the CMO, the investments in the manufacturing infrastructure and systems are geared toward meeting the anticipated needs of Avid's clients and Peregrine's advancing pipeline, including the potential commercialization of cancer drugs bavituximab and Cotara. Within the last quarter, Avid has enhanced its Reverse Osmosis Deionized (RODI) and Water for Injection (WFI) systems, which resulted in a 450% increase in water capacity, allowing for generation of sufficient water to support the anticipated increase in production.

In addition, in September, Avid secured a contract with Advanced BioScience Laboratories to provide development and large-scale manufacturing services to support cGMP production of an HIV envelope protein, as a component of a preventive vaccine against HIV infection. Avid is providing services from process verification and assay development, through to development of a robust and compliant process for large-scale manufacturing, in order to support cGMP production of the gp145 HIV envelope protein.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.3%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.